Hunter syndrome study pulled before it even started
NCT ID NCT05494593
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if giving a combination of immune-suppressing drugs (rituximab, methotrexate, and IVIG) alongside the standard enzyme therapy ELAPRASE could prevent patients with Hunter syndrome from developing harmful antibodies. It was designed for boys who had never received ELAPRASE before. However, the study was withdrawn by the sponsor before enrolling any participants, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Idursulfase (ELAPRASE), rituximab, methotrexate, intravenous immunoglobulin
What this could lead to
If successful, this approach could help prevent the body from rejecting enzyme replacement therapy, making treatment more effective for Hunter syndrome patients.
What could go wrong
The study was withdrawn before enrolling any participants, so no results are available. The immune tolerizing regimen adds significant medication and potential side effects without proven benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann and Robert H Lurie Childrens Hospital of Chicago
Chicago, Illinois, 60611, United States
-
Children's Hospital and Research Center at Oakland
Oakland, California, 94609, United States
-
Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, 55404, United States
-
NewYork-Presbyterian Morgan Stanley Children's Hospital
New York, New York, 10032, United States
-
Phoenix Childrens Hospital
Phoenix, Arizona, 85016, United States
-
Rady Childrens Hospital San Diego - PIN
San Diego, California, 92123, United States
-
The Cleveland Clinic Foundation
Twinsburg, Ohio, 44087, United States
-
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center
Torrance, California, 90502, United States